ABSI Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -4548% compared to Absci Corp.'s net margin of 16.99%. Absci Corp.'s return on equity of -60.55% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Absci Corp. has a consensus price target of $8.03, signalling upside risk potential of 162.37%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Absci Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Absci Corp. is more attractive than Alnylam Pharmaceuticals, Inc..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Absci Corp. quarterly revenues are $650K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Absci Corp.'s net income of -$29.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Absci Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 149.29x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -4548% compared to Absci Corp.'s net margin of 20.83%. Absci Corp.'s return on equity of -60.55% beat Johnson & Johnson's return on equity of 34.46%.

Absci Corp. has a consensus price target of $8.03, signalling upside risk potential of 162.37%. On the other hand Johnson & Johnson has an analysts' consensus of $241.08 which suggests that it could fall by -0.81%. Given that Absci Corp. has higher upside potential than Johnson & Johnson, analysts believe Absci Corp. is more attractive than Johnson & Johnson.

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.15% to investors and pays a quarterly dividend of $1.30 per share. Absci Corp. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Absci Corp. quarterly revenues are $650K, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Absci Corp.'s net income of -$29.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Absci Corp.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 149.29x versus 6.24x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -4548% compared to Absci Corp.'s net margin of -9.34%. Absci Corp.'s return on equity of -60.55% beat Pfizer Inc.'s return on equity of 8.69%.

Absci Corp. has a consensus price target of $8.03, signalling upside risk potential of 162.37%. On the other hand Pfizer Inc. has an analysts' consensus of $28.58 which suggests that it could grow by 0.92%. Given that Absci Corp. has higher upside potential than Pfizer Inc., analysts believe Absci Corp. is more attractive than Pfizer Inc..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.687%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.12% to investors and pays a quarterly dividend of $0.43 per share. Absci Corp. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Absci Corp. quarterly revenues are $650K, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Absci Corp.'s net income of -$29.6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Absci Corp.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 149.29x versus 2.56x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -4548% compared to Absci Corp.'s net margin of -304.24%. Absci Corp.'s return on equity of -60.55% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

Absci Corp. has a consensus price target of $8.03, signalling upside risk potential of 162.37%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 115.89%. Given that Absci Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Absci Corp. is more attractive than Recursion Pharmaceuticals, Inc..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Absci Corp. quarterly revenues are $650K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Absci Corp.'s net income of -$29.6M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Absci Corp.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 149.29x versus 19.01x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.